Perrigo Company plc is asking shareholders to vote at its April 30, 2026 AGM in Dublin on nine director nominees, auditor ratification, say‑on‑pay, a new 2026 Long‑Term Incentive Plan, and renewed Irish share issuance and pre‑emption opt‑out authorities.
The proxy highlights 2025 progress under Perrigo’s “3‑S” plan, including reported net sales of $4.3 billion, adjusted operating income of $622 million with a 14.6% margin, and adjusted EPS of $2.75, up 7%. Cost programs delivered roughly $163 million and $157 million in gross annualized savings, while an agreed Dermacosmetics divestiture is valued at up to €327 million.
Executive pay remains heavily performance‑based, with about 87% of the CEO’s target compensation at risk and 2025 annual incentive payouts below target. The board emphasizes strong governance, majority‑independent membership, proxy access, ESG and cybersecurity oversight, and strict anti‑hedging and share ownership policies.
Parker Geoffrey M. reported acquisition or exercise transactions in this Form 4 filing.
Perrigo Company director Geoffrey M. Parker received a grant of 3,024 Restricted Stock Units (RSUs) on March 13, 2026. Each RSU represents a contingent right to receive one Perrigo ordinary share, with this grant scheduled to vest on March 13, 2027.
The filing shows this as a compensation-related award, not an open-market purchase or sale. Following the grant, Parker holds 3,024 RSUs, 28,912 ordinary shares directly, 25,879 ordinary shares through a revocable trust where he and Jill Parker are trustees, and 17,375 ordinary shares through a Roth IRA.
Alford Bradley A reported acquisition or exercise transactions in this Form 4 filing.
Perrigo Company plc director Bradley A. Alford received a grant of 3,024 Restricted Stock Units on ordinary shares as equity compensation. Each unit represents a contingent right to receive one ordinary share, with the award scheduled to vest on March 13, 2027.
Following this grant, Alford holds 3,024 Restricted Stock Units and 41,160.148 ordinary shares directly. This is a compensation-related award, not an open-market purchase or sale, and reflects additional alignment with Perrigo’s equity over time as the units vest.
Perrigo Company plc executive Robert Willis, EVP & CHRO, reported compensation-related equity activity involving restricted stock units and ordinary shares. On March 6, 2026, he exercised performance-based and time-based restricted stock units into a total of 4,501 ordinary shares, with related non-derivative entries showing a reported price of $10.72 per share. The filing also shows a separate grant of 8,019 ordinary shares as a share award. To cover tax obligations, 6,524 ordinary shares were withheld through transactions coded “F,” which are not open-market sales. Following these transactions, Willis directly holds 47,935 Perrigo ordinary shares.
Perrigo Company plc CEO Patrick Lockwood-Taylor reported compensation-related equity activity. He exercised performance-based restricted stock units granted on July 10, 2023, converting 11,727 RSUs into the same number of ordinary shares at a stated price of $10.72 per share.
To cover tax obligations, 4,240 and 5,003 ordinary shares were withheld, leaving him with 102,135 ordinary shares held directly after these transactions. He also received a new grant of 13,839 restricted stock units, each representing one ordinary share, scheduled to vest in two equal annual installments beginning March 6, 2026.
Perrigo Company plc director Jonas Samuelson reported an equity award transaction involving Restricted Stock Units that convert into ordinary shares. On 6 March 2026, he exercised 3,066 Restricted Stock Units, receiving 3,066 ordinary shares at an exercise price of $10.72 per share. A subsequent transaction on the same date shows 1,748 ordinary shares were withheld to cover tax obligations, leaving him with 1,318 ordinary shares held directly after these transactions. The filing characterizes the RSUs as a contingent right to receive one Perrigo ordinary share per unit, with vesting tied to 6 March 2026.
Perrigo Company plc executive Eduardo Guarita Bezerra, EVP & Chief Financial Officer, reported multiple equity transactions in company shares. On March 6, 2026, he converted restricted stock units into ordinary shares and had some of those shares withheld to cover tax obligations.
The filing shows exercises of restricted stock units into 4,870 and 4,980 ordinary shares, with 1,186 and 1,213 ordinary shares disposed of through tax-withholding transactions at a stated price per share of 10.7200. He also received a grant or award of 22,208 ordinary shares. Following these movements, he directly owned 72,942 ordinary shares.
Perrigo Company plc, an Ireland‑incorporated, pure‑play self‑care company, files its annual report describing a diversified over‑the‑counter health and wellness business focused on consumer self‑care in North America and Europe. The company operates through two segments: Consumer Self‑Care Americas, centered on U.S. and Canadian store brands and select branded products, and Consumer Self‑Care International, focused largely on branded self‑care across Europe and Australia.
Perrigo emphasizes innovation in categories such as upper respiratory, nutrition, digestive health, pain and sleep‑aids, oral care, healthy lifestyle, skin care, women’s health and vitamins, minerals and supplements. It highlights major efficiency initiatives, including a three‑year Supply Chain Reinvention Program that simplified its global network and is being wound down after meeting primary objectives. As of June 27, 2025, voting stock held by non‑affiliates had an aggregate market value of $3,650,573,391, and as of February 24, 2026, there were 137,649,352 ordinary shares outstanding.
The report outlines an ESG strategy around climate action, packaging, responsible sourcing, and people and communities, including a net‑zero greenhouse gas target by 2040 and broad human‑capital programs for its roughly 8,100 employees. It also provides an extensive risk factor summary spanning competition, regulation, supply chain disruption, cybersecurity, tax changes and capital structure. Perrigo notes a $21.7 million 2025 tax benefit from the U.S. One Big Beautiful Bill Act while stating that new global tax rules and U.S. reforms are not expected to materially affect its overall financial position.
Perrigo Company plc reported fourth-quarter and full-year 2025 results showing a large non-cash goodwill impairment and solid adjusted performance. A $1.3 billion goodwill impairment drove a 2025 reported net loss of $1.40 billion, or $(10.12) per share, versus a $(1.17) loss a year earlier. Adjusted net income was $381.6 million, with adjusted EPS of $2.75, up 7.0% from $2.57, helped by cost-savings programs and currency tailwinds despite softer infant formula and OTC demand. Net sales fell 2.8% to $4.25 billion, with organic net sales down 2.4% as infant formula and contract manufacturing weakened, partially offset by share gains in key brands and store brands. The company completed its Supply Chain Reinvention Program and substantially finished Project Energize, together delivering over $320 million in annual run-rate benefits, and plans fewer than $20 million of additional costs through 2026.
For 2026, Perrigo introduced an ‘All In’ outlook that includes infant formula and divestitures, guiding to net sales growth of -5.5% to -1.5% and adjusted diluted EPS of $2.00 to $2.30. It also issued a ‘CORE Perrigo’ outlook excluding infant formula and previously announced divestitures, with reported net sales growth of -3.0% to +1.0%, CORE organic net sales of -3.5% to +0.5%, and CORE adjusted EPS of $2.25 to $2.55 versus 2025 CORE adjusted EPS of $2.52. Management is launching a new two‑year operational enhancement program, targeting $80–$100 million in annualized pre‑tax savings by the end of fiscal 2027 and reducing about 7% of its workforce. Perrigo also expects to close the sale of its Dermacosmetics business for up to €327 million in the second quarter of 2026, subject to customary conditions.
Fuller & Thaler Asset Management, Inc. filed a Schedule 13G reporting beneficial ownership of 7,824,758.81 shares of Perrigo Co plc common stock, representing 5.69% of the class as of 12/31/2025.
The California-based investment adviser reports sole voting power over 7,708,573.81 shares and sole dispositive power over 7,824,758.81 shares. The shares are held for clients under investment advisory arrangements and are certified as acquired and held in the ordinary course of business without any stated intent to influence control of Perrigo.